ライフサイエンスコーパス: haemodialysis

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 als of patients infected with HCV who are on haemodialysis.

2 atients with organ transplants or who needed haemodialysis.

3 ticoagulation, as they would be for standard haemodialysis.

4 dies were performed before, during and after haemodialysis.

5 te and renal function tests before and after haemodialysis.

6 rvival of patients is now equal to that with haemodialysis.

7 ccess grafts are the best option for chronic haemodialysis.

8 ing five patients had grafts functioning for haemodialysis 6-20 months after implantation, and a tota

9 vessels seem to provide safe and functional haemodialysis access, and warrant further study in rando

10 was implanted into the arms of patients for haemodialysis access.

11 We analysed 12-lead ECGs from 45 haemodialysis and 12 LQT2 patients.

12 New means of delivering haemodialysis are therefore required.

13 More frequent haemodialysis can improve both survival and quality of l

14 the abnormalities, which were all reduced by haemodialysis, closely resembled those in normal axons d

15 ic kidney disease (stage 4-5 with or without haemodialysis dependence) were randomly assigned to rece

16 Overall, 179 (76%) were haemodialysis-dependent, 122 (52%) had HCV genotype 1a i

17 ar haemodialysis were fitted with a wearable haemodialysis device for 4-8 h.

18 This wearable haemodialysis device shows promising safety and efficacy

19 sess the safety and efficiency of a wearable haemodialysis device.

20 percentage of patients because of dropout to haemodialysis for inherent complications of peritoneal d

21 re widely considered preferable to in-centre haemodialysis for many patients with ESKD in settings wh

22 Patients commencing on haemodialysis (HD) have an increased risk of cardiovascu

23 ients, because their removal by conventional haemodialysis (HD) is severely limited by their low free

24 MVs were isolated from the blood of 20 haemodialysis (HD), 17 peritoneal dialysis (PD) patients

25 erview of incidence, modality use (in-centre haemodialysis, home dialysis, or transplantation), and m

26 SKD worldwide who are treated with in-centre haemodialysis, overall survival is poor, but longer in s

27 ment, and can maintain anaemia management in haemodialysis patients when given intravenously at 4-wee

28 ee times per week for haemoglobin control in haemodialysis patients.

29 Commendable haemodialysis practice includes exceptionally high use o

30 nal cohort study to highlight differences in haemodialysis practices that affect survival and the exp

31 Haemodialysis presents an additional high-risk exposure

32 brils extracted from patients suffering from haemodialysis-related amyloidosis and those formed by se

33 This paper charts the development of haemodialysis, the cornerstone of renal replacement ther

34 Nine patients were studied during routine haemodialysis therapy.

35 d-stage renal disease who had been receiving haemodialysis through an access graft that had a high pr

36 e UK to allow patients to have more frequent haemodialysis treatments in hospital and satellite haemo

37 ght in February, 1996, all 126 patients in a haemodialysis unit in Caruaru, north-east Brazil, develo

38 ialysis treatments in hospital and satellite haemodialysis units.

39 y phase (0-3 months) and effectiveness after haemodialysis was started.

40 ients and toxicological studies of serum and haemodialysis water filters.

41 13.8] years) who were established on regular haemodialysis were fitted with a wearable haemodialysis

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。